文献速递慢性肾脏病

微粒姜黄素对慢性肾脏病进展的影响:MPAC-CKD随机临床试验

The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

这项随机双盲安慰剂对照试验纳入533例伴有白蛋白尿且eGFR在15至60 mL/min/1.73 m²之间的成人慢性肾脏病患者,比较微粒姜黄素90 mg/天与安慰剂治疗6个月的效果。结果显示,6个月时白蛋白尿变化在两组间无显著差异(几何均值比0.94,97.5%CI 0.82至1.08,P=0.32),eGFR变化亦无显著差异(组间均值差-0.22 mL/min/1.73 m²,97.5%CI -1.38至0.95,P=0.68)。结论认为每日90 mg微粒姜黄素未减缓白蛋白尿性慢性肾脏病的进展。

要点

  • 在伴有白蛋白尿的慢性肾脏病患者中,每日90 mg微粒姜黄素治疗6个月未显著改善白蛋白尿。
  • 微粒姜黄素组与安慰剂组的eGFR变化无显著差异。
  • 研究结论认为微粒姜黄素未减缓白蛋白尿性慢性肾脏病的进展。

核心结论

  • 每日90 mg微粒姜黄素治疗6个月未减缓白蛋白尿性慢性肾脏病的进展。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,随访6个月,纳入533例伴有白蛋白尿且eGFR在15至60 mL/min/1.73 m²之间的成人慢性肾脏病患者。
  • 纳入标准为随机化前3个月内随机尿白蛋白与肌酐比值>30 mg/mmol(265 mg/g)或24小时尿蛋白定量>300 mg,且eGFR在15至60 mL/min/1.73 m²之间。
  • 参与者按1:1随机分配接受微粒姜黄素胶囊(90 mg/天)或匹配安慰剂治疗6个月。
  • 共同主要结局为随机化后白蛋白尿和eGFR的变化。

主要发现

  • 共纳入533例参与者,姜黄素组265例中4例、安慰剂组268例中15例撤回知情同意或变得不符合条件。
  • 6个月时白蛋白尿变化在姜黄素组与安慰剂组间无显著差异(几何均值比0.94,97.5%CI 0.82至1.08,P=0.32)。
  • 6个月时eGFR变化在两组间无显著差异(组间均值差-0.22 mL/min/1.73 m²,97.5%CI -1.38至0.95,P=0.68)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Curcumin is a commonly used herbal supplement with anti-inflammatory and anti-fibrotic properties. Animal studies and small human trials suggest that curcumin reduces albuminuria in patients with chronic kidney disease (CKD). Micro-particle curcumin is a new, more bioavailable formulation of curcumin. METHODS: To determine whether micro-particle curcumin versus placebo slows the progression of albuminuric CKD we conducted a randomized, double-blind, placebo-controlled trial with 6-month follow-up. We included adults with albuminuria [a random urine albumin-to-creatinine ratio >30 mg/mmol (265 mg/g) or a 24-h urine collection with more than 300 mg of protein] and an estimated glomerular filtration rate (eGFR) between 15 and 60 mL/min/1.73 m2 within the 3 months before randomization. We randomly allocated participants 1:1 to receive micro-particle curcumin capsules (90 mg/day) or matching placebo for 6 months. After randomization, the co-primary outcomes were the changes in albuminuria and the eGFR. RESULTS: We enrolled 533 participants, but 4/265 participants in the curcumin group and 15/268 in the placebo group withdrew consent or became ineligible. The 6-month change in albuminuria did not differ significantly between the curcumin and placebo groups [geometric mean ratio 0.94, 97.5% confidence interval (CI) 0.82 to 1.08, P = .32]. Similarly, the 6-month change in eGFR did not differ between groups (mean between-group difference -0.22 mL/min/1.73 m2, 97.5% CI -1.38 to 0.95, P = .68). CONCLUSIONS: Ninety milligrams of micro-particle curcumin daily did not slow the progression of albuminuric CKD over 6 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02369549.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Weir MA, Walsh M, Cuerden MS, et al. The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial. Nephrol Dial Transplant. 2023. PMID: 36849161. doi:10.1093/ndt/gfad037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。